[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-563825-105":3,"detail-sidebar-cat-1-en-105":80,"doc-detail-563825-en":126},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","a-physicians-view-guide-for-patients-with-ntm-infections-updated-september-13-2019","A Physician’s View - Guide for Patients with NTM Infections - Updated September 13, 2019","","Patient-focused guidance for non-tuberculous mycobacteria (NTM) infections explains what NTM are and where they commonly persist in environments such as soil, water, and biofilms. It summarizes diseases caused by NTM, with emphasis on NTM lung disease, including epidemiology, environmental risk factors, routes of acquisition, and predisposing medical conditions. The guide also outlines diagnostic components and treatment considerations, including antibiotic choices, resistance, toxicity management, mucus clearance, nutrition, surgery, and strategies to reduce exposure.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/template/","Template",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/template/general/","General",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/template/a-physicians-view-guide-for-patients-with-ntm-infections-updated-september-13-2019/563825/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-physicians-view-guide-for-patients-with-ntm-infections-updated-september-13-2019/563825.png","ImageObject",442,249,{"name":42,"@type":43},"Well Done","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-10-12",true,{"@type":52,"interactionType":53,"userInteractionCount":33},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What are non-tuberculous mycobacteria (NTM), and where do they tend to be found?","Question",{"text":62,"@type":63},"NTM are cousins of the bacteria that cause tuberculosis and leprosy, but there are many types. They can persist in environmental niches such as soil, water, and biofilms in natural and man-made settings.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"What are common environmental and acquisition routes for NTM lung disease?",{"text":67,"@type":63},"Environmental “risk” factors include warm and humid conditions, living near bodies of water (especially turbid water), and exposure to soil through occupational or recreational activities. Acquisition occurs through inhalation of water, soil, and biofilm aerosols, and through aspiration of NTM-containing secretions from above (swallowing dysfunction) or from below (gastroesophageal reflux).",{"name":69,"@type":60,"acceptedAnswer":70},"How does the guide approach treatment decisions for NTM lung disease?",{"text":71,"@type":63},"Treatment considerations include deciding if and when to treat, using MAC treatment algorithms, selecting antibiotics, managing macrolide resistance, and addressing treatment outcomes. It also covers minimizing antibiotic toxicity while improving efficacy, plus mucus clearance mechanisms, nutrition, and the role of surgery.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},563825,1792110819,{"code":4,"msg":81,"data":82},"success",[83,88,93,98,103,108,113,118,123],{"id":84,"doc_module":22,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},11,"Presentations",90,"presentations",{"id":89,"doc_module":22,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},12,"Resumes",80,"resumes",{"id":94,"doc_module":22,"doc_module_name":25,"category_name":95,"show_sort_weight":96,"slug":97},14,"Invoices",70,"invoices",{"id":99,"doc_module":22,"doc_module_name":25,"category_name":100,"show_sort_weight":101,"slug":102},15,"Posters",60,"posters",{"id":104,"doc_module":22,"doc_module_name":25,"category_name":105,"show_sort_weight":106,"slug":107},16,"Social Media",50,"social-media",{"id":109,"doc_module":22,"doc_module_name":25,"category_name":110,"show_sort_weight":111,"slug":112},17,"Forms",40,"forms",{"id":114,"doc_module":22,"doc_module_name":25,"category_name":115,"show_sort_weight":116,"slug":117},18,"Letters",30,"letters",{"id":119,"doc_module":22,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},21,"Paper Templates",5,"papers-templates",{"id":124,"doc_module":22,"doc_module_name":25,"category_name":29,"show_sort_weight":4,"slug":125},158,"general-158",{"code":4,"msg":81,"data":127},{"doc_id":78,"user_id":128,"nickname":42,"user_avatar":129,"doc_module":22,"category_id":124,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":33,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":135,"language":136,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":12,"update_tm":140,"read_time":114},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","A Physician’s View: Guide for Patients with NTM Infections  \nEdward D. Chan, M. D.  \nNational Jewish Health, Rocky Mountain Regional Veterans Affairs Medical Center, University of Colorado Anschutz Medical Campus  \nDebbie Breslawsky  \nNTM Info & Research, Inc Board Member, National Jewish Health Trustee, Support Group Leader & Founder, NY (co leader), Palm Springs Area, California & Connecticut  \nPhilip Leitman (President), Amy Leitman, J. D. (Director of Policy and Advocacy), NTM Info and Research, Inc  \n1  \n Updated: September 13, 2019   \nTable of Contents  \n• What are non-tuberculous mycobacteria (NTM)? Where are NTM lurking? (3)  \n• Diseases caused by NTM (4)  \n• NTM lung disease – epidemiology (5)  \n• What environmental “risk” factors are associated with NTM lung disease? (6)  \n• NTM lung disease – how do we acquire it? (7)  \n• NTM lung disease – predisposing medical conditions (8)  \n• NTM lung disease – three main components required for diagnosis (9)  \n• NTM lung disease – radiographic manifestations (10)  \n• Treatment of NTM lung disease – what to consider when deciding if and when to treat (11)  \n• Treatment of NTM lung disease – MAC treatment algorithm (12)  \n• Treatment of MAC lung disease – antibiotics (13)  \n• Treatment of MAC lung disease – macrolide resistance (14)  \n• Treatment outcome for MAC lung disease (15)  \n• Treatment of M. abscessus complex lung disease – antibiotics (16-17)  \n• Treatment of NTM lung disease – antibiotic drug toxicity and means to minimize toxicity and increase efficacy (18-20)  \n• Amikacin (21)  \n• Inhaled liposomal amikacin (22)  \n• Tobramycin (23)  \n• Treatment of NTM lung disease – mucus clearance mechanisms (24)  \n• Foods that may affect mucus production (25)  \n• Treatment of NTM lung disease – nutrition (26)  \n• Treatment of NTM lung disease – role of surgery (27)  \n• What can you do to reduce exposure to NTM?– changes to your activities (28)  \n• What can you do to reduce exposure to NTM?– proactive measures (29)  \n• What can you do to reduce exposure to NTM?– changes to the environment (30)  \n• Skin and soft tissue infections – how do we acquire them? (31)  \n• NTM infection of internal organs other than the lungs – Who are at risks? (32)  \n• Appendix 1 – glossary of terms (33-35)  \n• Appendix 2 – oxygen (O2) delivery systems (36)  \n• Appendix 3 – pulse oximeter (37)  \n• Appendix 4 – use of Aerobika® (38)  \n• Appendix 5 – use of Acapella® (39)  \n• Appendix 6 – high frequency chest wall oscillation – vest (40)  \n• Appendix 7 – cleaning respiratory devices (41)  \n• Appendix 8 – if you must garden   (42)  \n• Appendix 9 – hints to prevent superimposed respiratory infections (43)  \n• Appendix 10 – peripherally-inserted central catheter (PICC) (44)  \n• Appendix 11 – port-catheter (45)  \n• Appendix 12 – proper order of multiple inhaled therapies (46)  \n• Appendix 13 – gastroesophageal reflux disease (47-48)  \n• Appendix 14 – Drugs that prolong QTc (49)  \n• Appendix 15 – Medicare (50)  \n• Appendix 16 – Top Ten Recommendations (51) 2  \n• Acknowledgments (52)  \nWhat are non-tuberculous mycobacteria (NTM)?  \nNTM are cousins of the bacteria that cause tuberculosis & leprosy but there are many types of NTM  \nMycobacterium tuberculosis  \nMycobacterium leprae  \nNTM  \nMore virulent: harder to treat  \nLess virulent: not as hard to treat  \nWhere are NTM lurking?  \nSoil, water, and biofilms in both natural & man-made niches  \n}  \nBiofilms (slimy film) can form on any solid surface in frequent contact with water  \nSlimy biochemical substance  \nNTM  \nBiofilms are like cities for microbes, consisting of a slimy biochemical substance (buildings) teeming with bacteria (people) .  \n3  \nDiseases caused by NTM  \n(can be classified into three main types)  \n• Isolated lung disease  \n• Skin and soft tissue infections  \n• Internal organs other than the lungs  \nWhite blood cells in an  \ninternal organ filled with live  \nM. intracellulare (pink color organisms) in a patient with advanced AIDS. But with AIDS thera","cbCaikeQpn9wPv4e","https://ap.wps.com/l/cbCaikeQpn9wPv4e","pdf",7308387,52,"English","# What are non-tuberculous mycobacteria (NTM)? Where are NTM lurking?\n# Diseases caused by NTM\n# NTM lung disease – epidemiology\n# What environmental “risk” factors are associated with NTM lung disease?\n# NTM lung disease – how do we acquire it?\n# NTM lung disease – predisposing medical conditions\n# NTM lung disease – three main components required for diagnosis\n# NTM lung disease – radiographic manifestations\n# Treatment of NTM lung disease – what to consider when deciding if and when to treat\n# Treatment of NTM lung disease – MAC treatment algorithm\n# Treatment of MAC lung disease – antibiotics\n# Treatment of MAC lung disease – macrolide resistance\n# Treatment outcome for MAC lung disease\n# Treatment of M. abscessus complex lung disease – antibiotics\n# Treatment of NTM lung disease – antibiotic drug toxicity and means to minimize toxicity and increase efficacy\n# Treatment – mucus clearance mechanisms, nutrition, and role of surgery\n# What can you do to reduce exposure to NTM?\n# Skin and soft tissue infections and NTM infection of internal organs\n# Appendices","[{\"question\":\"What are non-tuberculous mycobacteria (NTM), and where do they tend to be found?\",\"answer\":\"NTM are cousins of the bacteria that cause tuberculosis and leprosy, but there are many types. They can persist in environmental niches such as soil, water, and biofilms in natural and man-made settings.\"},{\"question\":\"What are common environmental and acquisition routes for NTM lung disease?\",\"answer\":\"Environmental “risk” factors include warm and humid conditions, living near bodies of water (especially turbid water), and exposure to soil through occupational or recreational activities. Acquisition occurs through inhalation of water, soil, and biofilm aerosols, and through aspiration of NTM-containing secretions from above (swallowing dysfunction) or from below (gastroesophageal reflux).\"},{\"question\":\"How does the guide approach treatment decisions for NTM lung disease?\",\"answer\":\"Treatment considerations include deciding if and when to treat, using MAC treatment algorithms, selecting antibiotics, managing macrolide resistance, and addressing treatment outcomes. It also covers minimizing antibiotic toxicity while improving efficacy, plus mucus clearance mechanisms, nutrition, and the role of surgery.\"}]","A Physician’s View - Guide for Patients with NTM Infections - Updated September 13, 2019 | PDF",1791838757]